Method of treating atopic dermatitis

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely allergology, and may be used for treating atopic dermatitis. That is ensured by the introduction of a preparation of a complex of cause significant allergens is combined with using antiallergic antimediators and topic steroids. The procedures of allergovaccination are conducted once a day in dose 0.1 ml to be increased by 0.1 ml daily to 0.9 ml in the 10-6 potency of cause significant allergens to 1 ml of the undiluted complex of allergens introduced once every 2 weeks for 3 years. The allergovaccination by cause significant allergens is performed with underlying pharmacological remission (control) of atopic dermatitis by external steroids and systemic therapeutic antimediators.

EFFECT: method provides higher clinical effectiveness in atopic dermatitis ensured by improved pharmacological control of the disease during the staged allergen-specific immune therapy, as well as enables effective arrest of the manifestations of atopic dermatitis with multiple sensibilisation.

1 ex


The invention relates to medicine, namely to Allergology, and can be used in the treatment of atopic dermatitis combined polyvalent etiology, persistent currents.

Currently, there is no doubt that the position that the most effective method of treatment of allergic diseases with uncontrolled and/or partially controlled sensitization is allergen-specific immunotherapy cause significant allergens, leading to the reduction of state-specific hypersensitivity and the formation of immune tolerance.

There is a method of treatment of persisting and seasonal atopic dermatitis household and pollen etiology by allergen-specific immunotherapy, consisting of subcutaneous injection cause significant allergens (allergen) in gradually increasing doses. Household and pollen sensitization is diagnosed when the results are at least 3 stages of the four support points diagnose allergies: allergic history, skin testing, provocative tests, and laboratory studies of specific antibodies of immunoglobulin E.

The disadvantage of this method is its low efficiency and the technical difficulties associated with the high cost of the time of the doctor-allergist is, and the patient, and the possibility of complications such as anaphylaxis [Bousquet j, Lockey R, Malling H.J., Alvarez-Cuesta E., et al. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Wold Healtg Organization. American academy of Allergy, Asthma and Immunology // Ann. Allergy Astgma Immunol. - 1998. - Vol.81. - P.401-405 (ID: 9860031)].

Closest to the claimed invention, the achieved result is a method for the treatment of atopic dermatitis household and pollen etiology, consisting of sublingual application cause significant domestic and pollen allergens: house dust, microclima, allergens library dust, trees, shrubs, grass and weeds [Bussmann, S., Bockenhoff A., H. Henke Et al. Does allergen-specific immunotherapy represent a therapeutic option for patients with atopic dermatitis? // J. Allergy Clin. Immunol. - 2006. - Vol.118. - P.1292-1298].

The disadvantage of this method is its low efficiency because of the broader spectrum of sensitization to allergens of other groups in this disease and constantly-recurrent nature of the disease, limiting the application of this method in the period of clinical manifestations.

The authors proposed a method for the treatment of atopic dermatitis with multiple sensitization: food, household, epidermal and pollen etiology that do not require a visit to the doctor-allergist and eliminating the risk of anaphylaxis to effectively stop the allergic process in the dermal tissue is x integument and conductive to long-term and sustained remission of the disease.

The technical result of the proposed method is to increase the effectiveness of treatment of atopic dermatitis by improving the pharmacological control of the disease during a phased allergen-specific immunotherapy according to the method proposed by the authors.

The technical result is achieved by the fact that in the proposed method, including sublingual application of allergen-specific immunotherapy simultaneously with the introduction of the drug complex cause-significant allergens, use intimidatory, anti-Allergy medications and topical steroids, and the procedure of allergological carried out 1 time per day from 0.1 ml increase in volume of 0.1 ml daily to 0.9 ml of 10-6the dilution of the complex cause-significant allergens to 1 ml not divorced complex allergens, input 1 every 2 weeks for 3 years, allowing you to effectively arrest the symptoms of atopic dermatitis with multiple (food, household, epidermal and pollen) sensitization.

The method is as follows.

Established complex causal important food allergens, domestic, epidermal or pollen etiology sublingual applied against the backdrop of pharmacological remission persistent atopic dermatitis, achieved by the system assignment of the complex anti-Christ. editornew funds and external therapy topical steroids, which leads to the penetration and "present" allergen load in the peripheral lymphoid education and a more rapid and reliable relief of atopic dermatitis, without the risk of systemic allergic reactions, with a subsequent gradual decrease in pharmacological load on the background of the effect of allergological.

The method is as follows.

Patients with atopic dermatitis sublingual impose a complex set of cause-significant allergens: food, household, epidermal or pollen etiology 1 times a day, starting with the 0.1 ml increase in volume of 0.1 ml daily to 0.9 ml of 10-6the dilution of the complex cause-significant allergens, then 10-5and 10-4in the same sequence dose 1 time per day, and 10-3in the same sequence and time doses the treatment was carried out every other day, 10-2in the same sequence of doses 2 times a week, 10-1in the same sequence doses of allergens to enter 1 time per week and then brought to 1 ml of the complex is not diluted allergens, which then assign 1 to every 2 weeks for 3 years.

Simultaneously with the sublingual application of the allergen on the skin as an anti-relapse therapy applied topical steroids, such as mometasone fuerat, 1 time per day, duration, and frequency is Yesenia which depends on the severity of skin allergic process, and inside designate intimidatory drugs such as cetirizine, 10 mg 1 time per day.

Clinical example

Catherine J., 25 years.

Clinical diagnosis: Atopic dermatitis, disseminated form adults, persisting for domestic (house dust 90S, dermatophagoides), pollen (birch, fire, sagebrush), food (whole egg and its components) sensitization.

Complained of symmetrically located itchy skin lesions with indistinct borders, growing in the room, in the afternoon and at night and decreasing on the street. In addition, notes increased rash and pruritus in the spring and summer, with the deterioration in the street and out of town, especially on a hot Sunny windy weather. Got sick at the age of about 3 years. From 10 to 18 years were noted improvement in reducing the amount of skin rashes and reduce the intensity of itching. With 18 years the disease has taken the nature of the flow described above. Treatment used antihistamines and topical steroid ointments, when you try lifting the rash recurred and/or amplified within 3-7 days.

The General condition is satisfactory, health does not suffer. On the skin symmetrically located erythematous-papular-squamous lesions on lichenoides background with enhanced natural when the tab with numerous excoriation. Palpable submandibular, axillary and inguinal lymph nodes.

During remission, due to cancellation of antihistamines for 5 days, with skin-scratch test defined a positive test with allergens: house dust to 90 ° C (++), microclean (Dermatophagoides) (+++), birch (+++), fire (++), wormwood (++), whole chicken egg (+) and its components: protein (+) and yolk (+). Provocative nasal tests with the same allergens were also positive.

Treatment by the present method.

The patient through daily use of antihistamines cetirizine (Zyrtec) in the morning and hydroxyzine (Atarax) in the evening, and montelukast (Singulair) during the day and topical steroid mometasone fourat (Elokim ointment) in the form of a dermatological compress at night after 3 weeks was achieved pharmacological remission (control of atopic dermatitis), while continuing in full-relapse treatment had been initiated sublingual allergen-specific immunotherapy (ASIT) complex allergens: house dust 90S, microclima (Dermatophagoides), birch, fire, sage, whole egg and its components with a dose of 0.1 ml of 10-6the dilution of 1 times a day and within 6 months was brought to 1 ml not divorced preparation of the complex of allergens that enter the th 1 time in 2 weeks. When the volume ASIT 0.5 ml of 10-3the dilution cancelled montelukast and hydroxyzine. With the continued control of atopic dermatitis at a dose of 0.5 ml of 10-1the dilution of the complex allergens cancelled cetirizine, and when the volume ASIT 1 ml not divorced complex allergens outdoor therapy in mode 2 times a week topical steroid mometazon replaced with cosmeceuticals.

After 6 months of therapy after cancelled pharmacological relapse support clinical manifestations of atopic dermatitis in the patient presents with xerodermia and light manifestations of pruritus in water hygiene procedures. By the present method ASIT was carried out for 3 years and was accompanied by sustained clinical remission of the disease.

Authors ' treatment of atopic dermatitis makes it possible to arrest the clinical manifestations of this disease. The advantage of the proposed method over the known is that the inventive method allows in a short time effectively arrest the symptoms of atopic dermatitis without the risk of systemic allergic reactions, with minimal supervision by a physician, allergist, and provides quality of life is restored in a short time from the start of treatment.

The method of treatment atopy the definition of dermatitis, including sublingual application of allergen-specific immunotherapy, characterized in that simultaneously with the introduction of the drug complex cause-significant allergens used intimidatory anti-Allergy medications and topical steroids, and procedures allergological carried out 1 time per day from 0.1 ml, with an increase in volume of 0.1 ml daily to 0.9 ml of 10-6the dilution cause significant allergens to 1 ml of undiluted complex allergens, input 1 every 2 weeks for 3 years, and the vaccination for Allergy cause significant allergens carried out on the background of pharmacological remission (control) atopic dermatitis outer steroid and systemic intimidatory drugs.


Same patents:

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly allergology and represents a pharmaceutical preparation for human allergy prevention, inhibition or elimination differing by the fact that an active ingredient is presented by genome DNA of probiotic, gram-positive bacteria and/or Lactobacillus gasseri PA 16/8 and/or Bifidobacterium bifidum MG 20/5 and/or Bifidobacterium longum SP 07/3 bacterial strains as viable and/or inactivated bacteria.

EFFECT: invention provides effective antiallergic action.

6 cl, 5 dwg

FIELD: chemistry.

SUBSTANCE: invention relates to 2,3-substituted pyrazine sulphonamides of formula (I), use thereof in treating allergic diseases, inflammatory dermatosis, immonological disorders and neurodegenerative disorders, as well as pharmaceutical compositions, having CRTH2 receptor inhibiting action and inhibiting chemoattractant receptor, homologous to the molecule expressed on T-helpers 2. in general formula .

A is selected from a group consisting of

, n denotes an integer independently selected from 0, 1, 2, 3 or 4; m equals 1 or 2; B is selected from a group consisting of phenyl or piperazinyl; R1 denotes hydrogen; R2 denotes phenyl, where R2 is optionally substituted with one or more substitutes selected from a group consisting of halogen, cyano, (C1-C6)alkyl; R3 is selected from a group consisting of (C1-C6)alkyl, aryl, heteroaryl, (C1-C6)alkylaryl, (C1-C6)alkylheteroaryl, (C3-C8)cycloalkyl and (C3-C8)heterocycloalkyl, where each of said (C1-C6)alkyl, aryl, heteroaryl, (C1-C6)alkylaryl, (C1-C6)alkylheteroaryl, (C3-C8)cycloalkyl and (C3-C8)heterocycloalkyl is optionally substituted with one or more substitutes selected from a group consisting of halogen, cyano, (C1-C6)alkyl, (C1-C6)alkoxy, heteroaryl, aryl, thioalkoxy and thioalkyl, or where said aryl, heteroaryl, (C1-C6)alkylaryl, (C1-C6)alkylheteroaryl, (C3-C8)cycloalkyl or (C3-C8)heterocycloalkyl can be condensed with one or more aryl, heteroaryl, (C3-C8)cycloalkyl or (C3-C8)heterocycloalkyl groups and can be substituted with one or more substitutes selected from a group consisting of (C1-C6)alkyl, alkoxy, aryl, heteroaryl, carboxyl, cyano, halogen, hydroxy, amino, aminocarbonyl, nitro, sulphoxy, sulphonyl, sulphonamide and trihaloalkyl; R7 is selected from a group consisting of hydrogen, (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, aryl, heteroaryl, (C3-C8)cycloalkyl, (C3-C8)heterocycloalkyl, carboxyl, cyano, amino and hydroxy; aryl is selected from phenyl or naphthyl; and heteroaryl is selected from pyridyl, indolyl, 3H-indolyl, benzimidazolyl, quinolizinyl.

EFFECT: high efficiency of using the compounds.

4 cl, 10 dwg, 46 ex

FIELD: chemistry.

SUBSTANCE: invention relates to an amine compound of formula (I), pharmaceutically acceptable addition salts, hydrates or solvates thereof, having immunodepressive effect , where R - H or P(=O)(OH)2; X - O or S; Y denotes -CH2CH2- or -CH=CH-; Z denotes C1-5-alkylene, C2-5-alkenylene or C2-5-alkynylene; R1 denotes CF3, R2 denotes C1-4-alkyl, substituted with OH or halogen; R3 and R4 independently denotes H < or C1-4-alkyl; A denotes optionally substituted C6-10-aryl, heteroaryl containing 5-10 ring atoms, where 1 or 2 atoms are selected from N, O and S, C3-7-cycloalkyl optionally condensed with optionally substituted benzene, or heterocycloalkyl containing 5-7 ring atoms, where 1 or 2 atoms are selected from N and O, where said substitutes are selected from C1-4-alkylthio, C1-4-alkylsulphanyl, C1-4-alkylsulphonyl, C2-5-alkylcarbonyl, halogen, cyano, nitro, C3-7-cycloalkyl, C6-10-aryl, C7-14-aralkyloxy, C6-10-aryloxy, optionally substituted with oxo or halogen, C2-3-alkyleneoxy, C3-4-alkylene or C1-2-alkylenedioxy, optionally substituted with halogen C1-4-alkyl or C1-4-alkoxy.

EFFECT: novel compound which is effective in reducing the level of lymphocytes in peripheral blood, suppresses tissue breakdown and exhibiting less side effects, such as bradycardia, is disclosed.

20 cl, 237 ex, 2 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly the preparation fexofenadine for allergic diseases. The pharmaceutical composition contains an effective amount of fexofenadine as an active ingredient, and excipients - hydroxypropyl cellulose, a filler, desintegrant glidant, a solubiliser and stearic acid salt. The filler represents a combination of lactose and starch. As glidant, the composition contains colloidal silicon dioxide.

EFFECT: pharmaceutical composition is presented in the form of tablets and is characterised by a high degree of release of the active substance and storage stability.

7 cl, 1 tbl, 3 ex

FIELD: food industry.

SUBSTANCE: invention is related to food industry and may be used for food allergy prevention. Hydrolysed by fermentative method egg whites with hydrolysis degree from 15% to 28% are applied in production of food compositions.

EFFECT: invention ensures tolerance to egg whites contained in food products with mammals.

5 cl, 5 dwg, 6 ex

FIELD: chemistry.

SUBSTANCE: described are novel diaminotriazole compounds of general formula

(values of radicals are given in the claim), pharmaceutically acceptable salts thereof, a pharmaceutical composition containing said compounds, a method of inhibiting JAK2 and JAK3 kinase activity and use of the novel compounds to produce a medicinal agent for treating several diseases.

EFFECT: high efficiency of the compounds.

19 cl, 3 tbl, 26 ex

FIELD: medicine.

SUBSTANCE: the invention relates to medicine and pharmaceutics, in particular, to creation of pharmaceutical composition in the form of suspension with anti-shock and anti-allergic action. The pharmaceutical composition with said actions contains dexamethasone sodium phosphate and “Micellate of calcium carbonate and magnesium”. The pharmaceutical compositions also contain sodium hyalurate, alcohol, Nipagin, fructose and water. A variant of the invention is a suspension which additionally contains sodium fluoride and ascorbic acid. Research was carried out and it proved that the offered pharmaceutical compositions have expressed specific pharmacological effect, they express anti-shock action, and have no toxic effect with various doses and various routes for experimental animals. The compositions have no irritant effect, sensibilizing action was not expressed.

EFFECT: the offered pharmaceutical compositions are effective and safe medication and can be used to treat state of shock, suitable for treatment of patients additionally suffering from diabetes mellitus.

2 cl, 2 ex, 1 tbl, 3 dwg

FIELD: chemistry.

SUBSTANCE: invention relates to novel diarylamine-containing compounds of formula (I) or formula (4b), pharmaceutically acceptable salts thereof, which have c-kit inhibiting properties. In formulae (I) and (4b), each R1 independently denotes H, -C(O)OH and -L1-C1-6alkyl, where L1 denotes -O- or -C(O)O-, or any two neighbouring R1 groups can together form a 5-6-member heterocyclic ring containing a nitrogen atom or an oxygen atom as a heteroatom, a 6-member heterocyclic ring with one or two nitrogen atom s as heteroatoms, optionally substituted with a C1-4alkyl, and R5 denotes hydrogen or C1-C6alkyl; values of radicals Ar and Q are given in the claim. The invention also relates to a pharmaceutical composition containing said compounds, and a method of treating diseases whose development is promoted by c-kit receptor activity.

EFFECT: more effective use of the compounds.

17 cl, 3 tbl, 9 ex

FIELD: food industry.

SUBSTANCE: invention relates to a non-allergenic food product. The food product includes an amino acid fraction containing at least one component chosen from the group consisting of amino acids and peptides with a degree of polymerisation 7 or less, and a lipid fraction containing at least one fatty acid chosen from the group consisting of arachidonic acid and docosahexanoic acid. The composition content of protein and other peptides with molecular weight 1000 daltons or more (in relation to dry weight) is less than 0.01 wt %, preferably - no less than 0.001 wt %, more preferably - no less than 0.0001 wt %. The food product is used for allergy diagnostics.

EFFECT: invention allows to produce a product which does not impart allergic reactions and is able to attenuate intensity of the patients' allergic reactions.

7 cl, 4 ex

FIELD: medicine.

SUBSTANCE: invention provides an IFA test system for detection of specific staphylococcus IgE-antibodies in blood serum of a patient with allergic diseases, hypersensitive to staphylococcus allergens; a method for detection of specific staphylococcus IgE-antibodies in blood serum of the patient with allergic diseases, hypersensitive to staphylococcus allergens, with using said test system; and a diagnostic technique for staphylococcus allergy.

EFFECT: application of the declared invention allows detecting staphylococcus allergy.

12 cl, 4 ex, 2 tbl, 1 dwg

FIELD: medicine.

SUBSTANCE: invention refers to veterinary microbiology. A method for growing atypical mycobacteria cultures on a liquid nutrient medium, culture inactivation by autoclaving at 120°C for 30 minutes, protein settling from a culture filtrate of each strain separately by trichloroacetic acid to the final concentration of 4%, re-settling by ammonium sulphate at 50% saturation, protein dialysis through a cellophane coating as against deionised water to remove salts; analysis of the protein solution for its activity in each atypical mycobacteria culture, mixing of the protein solutions in equal portions by the "ED" concentration, sterilising filtration of the solution, packaging and lyophilisation. As atypical mycobacteria cultures, M. intracellulare, M. scrofulaceum, M. fortuitum and M. smegmatis are used, while the atypical mycobacteria cultures are grown on the liquid nutrient medium for 2-3 weeks.

EFFECT: method provides high-quality differential diagnostic response on PPD tuberculin for mammals and cutting economic loss of induced PPD tuberculin responded animal killing.

3 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmacology and medicine, namely to a method for producing diagnostic allergens of a number of synanthropic insects, such as: Blattella germanica, Blatta orientalis, Pertplaneta americana cockroach Neuphoeta cinerea, Musca domestica, Tinea pelionella, Cimex lectularis, Monomorium pharaonis, Tegenaria derhami, Culex pipiens, Attagenus Smirnovi Zhan. For the method for producing the diagnostic allergen, initial raw materials are frozen synanthropic insects. The initial raw materials are grinded to particle size 1-3 mm, degreased by addition of ether in the ratio 1:3-4 to the raw materials; the raw materials are kept in ether during 15-20 min that is followed by removal of ether by mixture filtering; the raw materials are degreased again by ether, dried to complete ether removal; the completely fat-free raw materials are powdered. The prepared powder is extracted in two stages; the first stage involves pouring the powder with an extractant liquid 1:1 and mixing to a homogeneous suspension; and the second stage includes mixing the prepared suspension with the extractant liquid in the ratio 2:1 and agitating by shaking the suspension three times for 30 minutes every 1.5 hours at temperature 2-10°C for 3 days with daily correction of the pH value of the allergenic extract to 7.0-7.2.

EFFECT: invention provides extended range of the diagnostic allergens and creation of a highly effective preparation for the diagnostic diseases caused by sensitisation to synanthropic insects.

2 cl, 1 ex, 1 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to field of biotechnology, and describes method of obtaining preparation for carrying out application skin test, which includes mixing tested substance with carrier and solvent, as carrier used is gar-agar, as solvent - borate buffer pH 6.8-7.2, agar-agar in borate buffer is heated with mixing to complete dissolution of agar-agar, mixture is cooled to 40-45°C and tested substance in amount 10-50% of total volume of ready preparation is introduced, as tested substances used are their water solutions with concentrations, capable of inducing contact reactions of hypersensitivity.

EFFECT: method makes it possible to detect hypersensitivity to tested substances.

3 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine and concerns cat allergen fused proteins and application thereof. Substance of the invention involves a compositions containing a virus-like particle (VLP) or a viral particle and at least, one antigen, first of all at least, one cat antigen, and more specifically at least one cat antigen which is human allergen. In specific versions of the invention, said antigen represents cat antigen Fel d1 or its fragment covalently bound with the VLP.

EFFECT: invention can be applied for preparing vaccines first of all aimed at treatment and/or prevention of cat dander allergy and other cat antigens and allergens responses.

25 cl, 20 ex, 5 tbl, 4 dwg

FIELD: medicine, veterinary science.

SUBSTANCE: invention concerns veterinary medicine. Currently, for differentiating nonspecific tuberculin reactions in cattle, dried purified tuberculin is used for mammals and "КАМ" with considering the sensitisation pattern by the reaction intensity. A common complex allergen is produced by protein settling from M scrofulaceum No. 12-C and M intracellulare No. 13-H strain cultures with added allergen produced from Corynebacterium xerosis N1911, in amount 1350 units of activity. The presence of coryneformic bacteria allergen in the "КАМ" composition improves the efficacy of a simultaneous dried purified tuberculin test for mammals in differentiating the nonspecific coryneformic bacteria reactions.

EFFECT: use of the declared allergen allows to prevent unreasonable slaughter, as well as further diagnostic finding expenses.

2 tbl

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to allergology, and can be applied for treatment of allergic rhinitis of domestic etiology. For this purpose in treatment included is allergen-specific immunotherapy with sublingual introduction of cause-significant allergen. Simultaneously hirudotherapy with application of medical leech on skin in region of oral cavity bottom projection is carried out. Procedures are carried out 2 times per week, starting from 0.1 ml 10-6 degree of dissolving of cause-significant allergen and bringing up to 0.5 ml of undissolved allergen, which after that is introduced 1 time per 2 weeks during 3 years.

EFFECT: invention allows to increase treatment efficiency due to increase of cause-significant allergen penetration into system of organs of mucosal immunity of upper airways.

1 ex

FIELD: medicine.

SUBSTANCE: present invention concerns medical products, particularly a pharmaceutical product for introduction of allergen that contains high-soluble solid dosage form introduced through tunica mucosa of mouth and containing matrix made by freeze drying from the solution containing 3-6.5 wt % pre-gelled starch and 3-5.5 wt % mannitol, or from the solution containing 2-10 wt % fish gelatine and 1-10 wt % mannitol; and allergen. Besides, invention concerns the method for making the specified product, a multidosage container, a set for allergy treatment, to the method of treating and applying the specified product.

EFFECT: preparation of allergen as a high-soluble uncompacted dosage form which is high-soluble, stable and low-fragile enough.

99 cl, 25 tbl, 1 ex

FIELD: medicine, pharmacology.

SUBSTANCE: method comprise salt-water extraction from raw material using Evans-Cook extraction liquid, mites cultivation during from 3 to 4 months, at temperature 25±2°C and relative air humidity 73±3%, on house dust and bristle. As initial basis, the mix of house dust mites Dermatophagoides farina or Dermatophagoides pternissinus culture and culture medium, including excrements, cast off skins, and food debris, is used. Salt-water extraction from raw material is performed during three days, after mixing it and homogenization with glass powder; the maintained incubation temperature is 2° to 10°C; the extraction material being shaken for 30 minutes three times a day with 1.5 hour intervals. Extraction completed, the supernatant liquor is decanted and centrifuged at 5000 to 6000 rpm for 30-40 minutes, then it is filtered through paper filter; in consequence sterilization through filtering, 3 to 4 months mother solution stabilisation, and bottling are carried out; the finished preparation is produced.

EFFECT: invention provides producing high effective treatment allergen in simplified process technology.

2 ex

FIELD: medicine.

SUBSTANCE: present invention refers to medicine and concerns microparticles containing sphere mainly consisting of cross-linked agarose carbohydrate and allergen covalently bonded with sphere, applied for immune system disturbance treatment. Used allergen is produced of plant pollen, specifically of timothy grass pollen. Application of specified microparticles provides effective treatment for patients suffering from allergy, as well as reduces by-effects of parenteral introduction.

EFFECT: development of effective method of allergy treatment and prevention.

9 cl, 4 dwg, 1 tbl, 5 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, specifically to conjugates of hydroxyalkyl starch and allergen, in which at least one hydroxyalkyl starch is covalent bonded with allergen for hyposensitisation. Conjugates HAS-allergen provide epitope profile comparable to natural, that enables to increase immunotherapy efficiency.

EFFECT: increasing of immunotherapy efficiency.

14 cl, 5 dwg

FIELD: medicine, radiation biology.

SUBSTANCE: invention proposes a method for preparing allergenic preparation used for diagnosis of body radiation injures. Method involves irradiation of potato tubers by the dose 350-400 Gr, the following extraction of quinoid radiotoxin by extraction with ethanol followed by removing extractant in rotary evaporator and additional extraction with ethyl acetate. The final prepared fraction is subjected for chromatography and separated in the system: (a) 2% acetic acid, and (b) mixture benzene - acetic acid - water in the ratio = 2:4:1, respectively. The prepared allergenic fraction is eluted with 2% acetic acid solution and standardized by dry matter as measured for 1 mg/cm3. Also, invention proposes a method for diagnosis of body radiation injures involving intracutaneous administration of specific allergen and detection of autosensitization symptom. Diagnosis of radiation diseases is proved by the allergy index. Proposed methods provide preparing the specific radiation allergen for detection of radiosensitization of body and to carry out diagnosis of radiation disease. Invention can be used in radiation biology.

EFFECT: improved preparing method, improved method for diagnosis.

1 tbl, 3 ex